Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06632002

Diabetes-specific Formulas on Nutritional Outcomes in Individuals With Diabetes Who Require Nutritional Support

The study aims to demonstrate the non-inferiority of diabetes-specific formula (DSF)1 compared to DSF2 in individuals with type 1 diabetes, type 2 diabetes or prediabetes and who are at nutritional risk.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Age range

21 year–90 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Chung Shan Medical University

Taichung, 40201, Taiwan

About this study

This is a randomized, double-blind, parallel, non-inferiority study. Eligible participants will be randomly allocated (at 1:1 ratio) to one of two groups: DSF1 (experimental group) or DSF2 (control group). Both groups will incorporate one serving of the DSF into their daily diet, in addition to receiving standard of care for diabetes. The total expected duration of the study is up to 104 days, including a run-in period of up to 14 days, followed by an intervention period of 90 days. At Day 1, participants will be randomized into one of the two groups (n = 50 per group): DSF1 or DSF2. Participants will start the intervention on Day 1 and complete the intervention on Day 90.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Participants are eligible to be included in the study only if all of the following criteria apply:

  • Has any of the following types of diabetes:
  • Type 1 diabetes
  • Type 2 diabetes
  • Prediabetes
  • Has MNA-SF score of ≤ 11
  • Serum albumin less than 4.0 g/dL
  • Energy or protein intake less than recommended
  • BMI less than 30.0 kg/m2
  • Either a male or a non-pregnant, non-lactating female, at least 6 weeks postpartum prior to the study
  • Female of childbearing potential to use an effective method of birth control
  • Chronic medication type and dose to be constant and maintained throughout the study
  • Willing to follow the protocol throughout the study
  • At least a two-week washout period between the completion of a previous research study and start in current study
  • Willing to refrain from taking non-study diabetes-specific formula over the course of the study.

Exclusion criteria

Participants are excluded from the study if any of the following criteria apply:

  • Has a screening HbA1c level less than 5.0% or ≥ 10%
  • Has a current infection, inpatient surgery or received systemic corticosteroid treatment in the last 3 months; or received antibiotics in the last 3 weeks
  • Has active malignancy within the last 5 years
  • Has significant cardiovascular event within 6 months prior to the study or history of congestive heart failure
  • Has end-stage organ failure or is post-organ transplant
  • Has current or history of renal disease or on dialysis or severe gastroparesis
  • Has current hepatic disease
  • Has a recent acute infection, physiologic stress or trauma within 1 month prior to the study
  • Has had bariatric surgery including gastric balloon; history of gastrointestinal disease or intestinal surgery that can interfere with consumption or digestion or absorption of study product
  • Has a chronic, contagious, infectious disease
  • Has eating disorder, severe dementia or delirium, history of significant neurological or psychiatric disorder, alcoholism, substance abuse or other conditions that may interfere with study product consumption or compliance with study procedures
  • Taking any herbals, dietary supplements or medications during the past 4 weeks prior to the study
  • Using diabetes-specific formula(s) or oral nutritional supplement formula(s) in more than one eating occasion per week within the past 3 months
  • Has clotting or bleeding disorders
  • Has blood or blood-related diseases
  • Has received blood transfusion within the last 3 weeks
  • Has allergy or intolerance to the study product
  • Anticipated poor compliance to the study as assessed by the Investigator
  • Participates in another study that has not been approved as a concomitant study by Abbott Nutrition

Treatment and study plan

DSF1

Other

220 mL

DSF2

Other

220 mL

Standard of Care (SOC)

Other

Standard of care

Primary outcomes

  1. Serum albumin

    Time frame: Study Day 1 to Day 90

    Change in serum albumin levels from baseline to Day 90

Secondary outcomes

  1. Serum albumin

    Time frame: Study Days 45 and 90

    Serum albumin levels

  2. Malnutrition risk

    Time frame: Study Days 45 and 90

    Mini Nutritional Assessment - Short Form (MNA®-SF) a validated screening tool for identifying elderly persons who are at risk for malnutrition, or who are already malnourished. It classifies participants into one of three categories:

    • Normal nutritional status/score =12 to 14 points,
    • At risk of malnutrition/score = 8 to 11 points,
    • Malnourished/score = 0 to 7 points. Minimum point = 0, Maximum points = 14. Lower score indicates worse outcome, i.e., at risk of malnutrition or malnourished.
  3. Malnutrition risk

    Time frame: Study Days 45 and 90

    Malnutrition Universal Screening Tool (MUST) is a widely used screening tool for malnutrition. It classifies participants into one of three nutrition status categories:

    • Low risk/score = 0,
    • Medium risk/score = 1,
    • High risk/score ≥ 2. Minimum value = 0, Maximum value = 6. Higher score indicates worse outcome, i.e., increased risk of malnutrition.
  4. Serum prealbumin

    Time frame: Study Days 45 and 90

    Serum prealbumin levels

  5. Body weight

    Time frame: Study Days 45 and 90

    Body weight measured in kg

  6. Body mass index (BMI)

    Time frame: Study Days 45 and 90

    Calculated as weight (kg)/height (m)2

  7. Mid arm circumference

    Time frame: Study Days 45 and 90

    Mid arm circumference measured in cm

  8. Mid arm muscle circumference

    Time frame: Study Days 45 and 90

    Mid arm muscle circumference measured in cm

  9. Triceps skinfold thickness

    Time frame: Study Days 45 and 90

    Triceps skinfold thickness measured in mm

  10. Calf circumference

    Time frame: Study Days 45 and 90

    Calf circumference measured in cm

  11. Waist circumference

    Time frame: Study Days 45 and 90

    Waist circumference measured in cm

  12. Hip circumference

    Time frame: Study Days 45 and 90

    Hip circumference measured in cm

  13. Waist-to-hip-ratio

    Time frame: Study Days 45 and 90

    Waist-to-hip-ratio

  14. Hemoglobin A1c (HbA1c)

    Time frame: Study Days 45 and 90

    HbA1c levels

  15. Fasting plasma glucose

    Time frame: Study Days 45 and 90

    Fasting plasma glucose levels

  16. 2-hour postprandial glucose

    Time frame: Study Days 45 and 90

    2-hour postprandial glucose levels

  17. Glycated albumin

    Time frame: Study Days 45 and 90

    Glycated albumin levels

  18. Triglycerides

    Time frame: Study Days 45 and 90

    Triglycerides levels

  19. High density lipoprotein (HDL) cholesterol

    Time frame: Study Days 45 and 90

    HDL cholesterol levels

  20. Low density lipoprotein (LDL) cholesterol

    Time frame: Study Days 45 and 90

    LDL cholesterol levels

Other outcomes

  1. Energy, macronutrient and micronutrient intakes

    Time frame: Study Days 45 and 90

    A 3-day Dietary Record (two weekdays and one weekend day) will be completed by participant for the week prior Study Day 45 and 90 and evaluated by a dietitian. Nutrient analysis will be performed using a dietary analysis program.

  2. Energy, macronutrient and micronutrient adequacy

    Time frame: Study Days 45 and 90

    Nutrient adequacy will be determined by comparing nutrient intakes (outcome No. 21) against sex- and age- specific local recommended nutrient intakes (RNI).

  3. Product intake compliance

    Time frame: Study Days 90

    Compliance to study product prescribed over 90-day intervention period

  4. Adverse events

    Time frame: Study Day 1 to Day 90

    Reported adverse events for assessment of safety and tolerability

Sponsors and collaborators

Lead sponsor

Abbott Nutrition

Industry

Registry information

Official study title

A Randomized, Double-blind, Non-inferiority Trial of a New Diabetes-specific Formula Compared to an Existing Diabetes-specific Formula on Nutritional Outcomes in Individuals With Diabetes Who Require Nutritional Support

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Oct 8, 2024
Registry last updated
Mar 9, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.